Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | TLR2 | O60603 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17738113 | 0.98 | HTT (0.56) | HTTMEN1THRBKMT2AMAPT | |
| SCHEMBL25921526 | 0.98 | HTT (0.56) | HTTMEN1THRBKMT2AMAPT | |
| SCHEMBL26280466 | 0.98 | HTT (0.56) | HTTMEN1THRBKMT2AMAPT | |
| SCHEMBL8979958 | 0.98 | EPHX1 (0.52) | HTTMEN1THRBKMT2AMAPT | |
| SCHEMBL14759886 | 0.95 | EPHX1 (0.56) | HTTMEN1THRBKMT2AMAPT | |
| SCHEMBL19418439 | 0.95 | EPHX1 (0.56) | HTTMEN1THRBKMT2AMAPT | |
| SCHEMBL17479927 | 0.95 | EPHX1 (0.56) | HTTMEN1THRBKMT2AMAPT | |
| SCHEMBL8378703 | 0.95 | EPHX1 (0.56) | HTTMEN1THRBKMT2AMAPT | |
| SCHEMBL17479934 | 0.95 | EPHX1 (0.56) | HTTMEN1THRBKMT2AMAPT | |
| SCHEMBL17479925 | 0.95 | EPHX1 (0.56) | HTTMEN1THRBKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12357631-B2 | Pyrrolo[2,3-B]pyridin derivatives as inhibitors of influenza virus replication | COCRYSTAL PHARMA, INC. (US) | 2025-07-15 | — | — | US | disclosed |
| EP-3829719-B1 | PYRROLO[2,3-B]PYRIDIN DERIVATIVES AS INHIBITORS OF INFLUENZA VIRUS REPLICATION | COCRYSTAL PHARMA INC (US) | 2025-04-02 | — | — | EP | disclosed |
| CN-112638477-B | Pyrrolo [2,3-B ] pyridine derivatives as inhibitors of influenza virus replication | 共晶制药公司 | 2024-01-26 | — | — | CN | disclosed |
| CN-110637022-B | Pyrrolopyrimidine derivatives as inhibitors of influenza virus replication | 共晶制药公司 | 2022-09-16 | — | — | CN | disclosed |
| US-20220185831-A1 | STAT3 PROTEIN DEGRADERS | UNIV MICHIGAN REGENTS (US) | 2022-06-16 | — | — | US | disclosed |
| EP-3829719-A1 | PYRROLO[2,3-B]PYRIDIN DERIVATIVES AS INHIBITORS OF INFLUENZA VIRUS REPLICATION | Cocrystal Pharma, Inc. (US) | 2021-06-09 | — | — | EP | disclosed |
| US-11014941-B2 | Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication | COCRYSTAL PHARMA, INC. (US) | 2021-05-25 | — | — | US | disclosed |
| US-11014941-B2 | Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication | COCRYSTAL PHARMA, INC. (US) | 2021-05-25 | — | — | US | disclosed |
| US-20210121462-A1 | PYRROLO[2,3-B]PYRIDIN DERIVATIVES AS INHIBITORS OF INFLUENZA VIRUS REPLICATION | COCRYSTAL PHARMA, INC. | 2021-04-29 | — | — | US | disclosed |
| US-20210121462-A1 | PYRROLO[2,3-B]PYRIDIN DERIVATIVES AS INHIBITORS OF INFLUENZA VIRUS REPLICATION | COCRYSTAL PHARMA, INC. | 2021-04-29 | — | — | US | disclosed |
| CN-112638477-A | Pyrrolo [2,3-B ] pyridine derivatives as inhibitors of influenza virus replication | 共晶制药公司 | 2021-04-09 | — | — | CN | disclosed |
| US-20200123177-A1 | PYRROLOPYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF INFLUENZA VIRUS REPLICATION | COCRYSTAL PHARMA, INC. | 2020-04-23 | — | — | US | disclosed |
| US-20200123177-A1 | PYRROLOPYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF INFLUENZA VIRUS REPLICATION | COCRYSTAL PHARMA, INC. | 2020-04-23 | — | — | US | disclosed |
| WO-2020023813-A1 | PYRROLO[2,3-B]PYRIDIN DERIVATIVES AS INHIBITORS OF INFLUENZA VIRUS REPLICATION | COCRYSTAL PHARMA, INC. (US) | 2020-01-30 | — | — | WO | disclosed |
| WO-2020023813-A1 | PYRROLO[2,3-B]PYRIDIN DERIVATIVES AS INHIBITORS OF INFLUENZA VIRUS REPLICATION | COCRYSTAL PHARMA, INC. (US) | 2020-01-30 | — | — | WO | disclosed |
| CN-110637022-A | Pyrrolopyrimidine derivatives as inhibitors of influenza virus replication | 共晶制药公司 | 2019-12-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11014941-B2 | Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication | ITPA, POLR2H, POLR2E | HTT 3679/4885MEN1 4650/4885THRB 4207/4885 |
| US-20220185831-A1 | STAT3 PROTEIN DEGRADERS | STAT3, JAK2, STAT5A | HTT 1422/4885MEN1 3114/4885THRB 535/4885 |
| US-20210121462-A1 | PYRROLO[2,3-B]PYRIDIN DERIVATIVES AS INHIBITORS OF INFLUENZA VIRUS REPLICATION | PIR, PNPO, IDO1 | HTT 4570/4885MEN1 4307/4885THRB 2542/4885 |
| US-20200123177-A1 | PYRROLOPYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF INFLUENZA VIRUS REPLICATION | ITPA, POLR2H, POLR2E | HTT 3679/4885MEN1 4650/4885THRB 4207/4885 |
| US-12357631-B2 | Pyrrolo[2,3-B]pyridin derivatives as inhibitors of influenza virus replication | PIR, PNPO, IDO1 | HTT 4570/4885MEN1 4307/4885THRB 2542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.